

Practical and Scalable Synthesis of Orthogonally Protected-2-Substituted Chiral Piperazines

Srinivas Chamakuri^{‡#*}, Manuj M. Shah[†], David C. H. Yang[†], Conrad Santini^{#§}, Damian W. Young^{‡#§†*}

[‡]Department of Pharmacology and Chemical Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 USA

[#]Center for Drug Discovery, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 USA

[§]Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 USA

[†]Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005 USA

Author Information

Corresponding Author

*E-mail: Damian.Young@bcm.edu

*E-mail: Srinivas.Chamakuri@bcm.edu

Keywords: chiral piperazines, orthogonally protected diamine, annulation, vinyl diphenyl sulfonium salt, 1,4-diazepanes and 1,4-diazocanes.

Supporting Information Table of Contents


Content	Page
General methods, reaction optimization, experimental procedures and NMR data	S2-S31
¹ H, ¹³ C NMR spectra of all new compounds	S32-S182
Chiral HPLC data for 4e, 4c, 4d	S183-S188

General Methods.

All starting materials and reagents were purchased from commercial sources and used without further purification. Solvents were purchased as either anhydrous grade products in sealed containers or reagent grade and used as received. All reactions were carried out in dry glassware under a nitrogen atmosphere using standard disposable or gastight syringes, disposable or stainless steel needles, and septa. Stirring was achieved with magnetic stir bars. Flash column chromatography was performed with SiO₂ (230-400 mesh) or by using an automated chromatography instrument with an appropriately sized column. Thin layer chromatography was performed on silica gel 60F₂₅₄ plates (E. Merck). Non-UV active compounds were visualized on TLC using one of the following stains: KMnO₄, ninhydrin, *p*-anisaldehyde. ¹H and ¹³C NMR spectra were recorded on an instrument operating at either 600MHz, and 151MHz respectively. LCMS data were collected using an HPLC instrument coupled to a low resolution mass spectrometer with single quadrupole ionization operating in either positive or negative ion mode. The analytical method utilized a C₁₈ column (2.1 × 50 mm, 1.8 μm) eluting with a linear gradient of 95%/5% water/CH₃CN (modified with 0.05% formic acid; T = 0 min flow = 0.35 mL/min) to 95%/5% CH₃CN/water (T = 3.5 min flow = 0.5 mL/min) then 95%/5% CH₃CN/water to T = 5min (0.5 mL/min). Peak detection was done at 254 nm and 230 nm for UV active compounds. For non-UV active compounds total ion count was used. High-resolution mass spectrometry (HRMS) spectra were obtained on a Thermo Scientific Q Exactive hybrid quadrupole-Orbitrap mass spectrometer equipped with a HESI source and using lock masses for correction. Samples were introduced into the HRMS via reversed phase HPLC on an Accucore Vanquish C18+ column (2.1 × 100 mm, 1.5 μm) eluting with a linear gradient of 95%/5% water/acetonitrile (modified with 0.1% formic acid) to 10%/90% water/acetonitrile over 8 min. Chiral HPLC analysis of piperazines was carried out on an instrument with automated 6-column array (Daicel ChiralPak I-series, IA through IF, 4.6 × 150 mm, 5 μm). Racemates were screened using a heptane (A)/ethanol (B) gradient (flow = 1 mL/min) as follows: T = 0 min (%A/%B) 95/5, T = 1 min 95/5, T = 11 min 10/90 (linear gradient), T = 13 min 10/90, T = 13.1min 95/5, T = 15min 95/5. Racemates that gave unsatisfactory resolution of enantiomers were rescreened using the above gradient with *i*PrOH instead of EtOH. Additional editing of the gradient or the use of an isocratic mobile phase to optimize separation was carried out as needed. Chiral materials were analyzed using optimized conditions and their traces were compared to the racemic traces for determination of enantiomeric ratio (er).

To determine our limit of detection (LOD) by chiral HPLC, 5 μL aliquots of 2 mg/mL stocks (10 ng injections) of purified protected scaffolds were subjected to chiral HPLC analysis to resolve and quantify enantiomers and determine enantiomeric ratios. Scouting solvent conditions across six 4.6 mm x 150 mm chiral columns (ChiralPak IA-IE) identified chromatographic conditions for every compound that successfully effected baseline resolution of the enantiomers of the racemic products. Absorbance at 254 nm (nosyl or benzyl) was used to detect and quantify the amount of scaffold. Serial dilutions of the 2 mg/mL stocks established that our LOD is approximately 0.02 ng/injection, or 0.2% of the total material loaded under these conditions. Therefore, the limit of our detection of enantiomeric ratio is ≥99.8:0.2. All chiral traces of the scaffolds are included in the Supplementary Information.

All NMR chemical shifts are quoted on the δ scale and were referenced to residual non-deuterated solvent as an internal standard. Signal multiplicities are described using the following abbreviations: s = singlet, d = doublet, t = triplet, b = broad, quar = quartet, quin = quintet, m = multiplet, v = very; abbreviations are combined, *e.g.* vbs = very broad singlet.



S.No	Reagent	Condition	Outcome	Remarks
1	2	DBU, DCM, rt	3	Slow, not clean
2	2	NaH, DCM, rt	no product	-
3	2	NaH, THF, rt	no product	-
4	2	NaH, THF, 60 °C	complex mixture	-
5	2	DIPEA, ACN, rt	Michael adduct	very slow
6	2	DIPEA, DMF, rt	Michael adduct	slow
7	2	DIPEA, DCM, rt	3	-
8	2	Cs ₂ CO ₃ , DCM, rt	3	-
9	2'	NaH, DCM, rt	no product	-
10	2'	NaH, THF, rt	no product	-
11	2'	DBU, DCM, rt	Michael adduct	-
12	2'	DIPEA, DCM, rt	Michael adduct	-

Table S1: Reaction optimization

General Experimental Procedures:

Synthesis of Bromide Intermediate: Into a round bottom flask equipped with magnetic stir bar and septum under nitrogen, the bisprotected chiral diamine (**1 equiv.**) was dissolved in dichloromethane and 2-bromoethyl-diphenylsulfonium triflate (**1.25 equiv.**) was added followed by diisopropylethylamine (**3 equiv.**). The reaction was allowed to stir at room temperature under nitrogen for 16h, after which time the TLC and LCMS showed no starting material remaining. The reaction was worked up by diluting with dichloromethane and washed with water and brine. The organic phase was collected and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure bromide product.


Method A: Into a round bottom flask equipped with magnetic stir bar and septum, the bromide compound (**1 equiv.**) was dissolved in dry THF and NaH (**2 equiv.**) was added at room temperature and the reaction was allowed to stir at room temperature under nitrogen. After 5h, LCMS and TLC showed complete consumption of the starting material. The reaction was quenched by adding cold water and then diluted

with ethyl acetate and washed with brine solution. The organic phase was collected and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure piperazine product.


Method B: Into a round bottom flask equipped with magnetic stir bar and septum, the bromide compound (**1 equiv.**) was dissolved in dichloromethane and TFA (10% TFA in DCM, V/V, 10 mL/mmol) was added and allowed to stir at room temperature under nitrogen. After 2h the starting material was consumed according to TLC and LCMS. The volatiles were evaporated under reduced pressure and then redissolved in toluene and evaporated to remove excess TFA. The mixture was diluted with DCM and washed with saturated aq NaHCO₃ solution. The organic phase was collected and dried over anhydrous Na₂SO₄. and the solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (methanol:DCM) provided pure piperazine product.

Method C: Into a round bottom flask equipped with magnetic stir bar and septum, the bromide compound (**1 equiv.**) was dissolved at room temperature in dichloromethane and tetrabutylammonium iodide (TBAI; **equiv.**) added. Upon complete dissolution, trimethylsilyltrifluoromethanesulfonate (TMSOTf; **2 equiv.**) was added dropwise by syringe. The reaction allowed to stir at room temperature for 1h under nitrogen, after which time TLC and LCMS indicated complete consumption of starting material. The reaction was diluted with DCM (50 mL) and the organic phase was washed by saturated aq NaHCO₃ and then sat aq Na₂S₂O₃ solution (30 mL). The organic phase was collected and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (methanol:DCM) provided pure piperazine product.


Method D: Into a round bottom flask equipped with magnetic stir bar and septum, the bromide compound (**1 equiv.**) was dissolved in dichloromethane and TFA (10% TFA in DCM, V/V, 10 mL/mmol) was added and allowed to stir at room temperature under nitrogen. After 2h the starting material was consumed according to TLC and LCMS. The volatiles were evaporated under reduced pressure and then redissolved in toluene and evaporated to remove excess TFA. The mixture was dissolved in dry THF and K₂CO₃ (**5 equiv.**) was added at room temperature and the reaction was allowed to stir at room temperature under nitrogen. After 16h, LCMS and TLC showed complete consumption of the starting material. The reaction was quenched by adding water and then diluted with ethyl acetate and washed with brine solution. The organic phase was collected and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (methanol:DCM) provided the pure product.



Tert-butyl (S)-1-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propan-2-yl)carbamate (3a):
 Molecular Formula: C₁₆H₂₄BrN₃O₆S; Rf (40% ethyl acetate/hexanes): 0.35; ¹H NMR (600 MHz, CDCl₃) δ 8.04-8.01 (m, 1H), 7.75-7.69 (m, 2H), 7.67-7.64 (m, 1H), 4.62-4.54 (m, 1H), 3.92-3.87 (m, 1H), 3.76-3.65 (m, 2H), 3.52-3.39 (m, 3H), 3.26 (dd, *J* = 14.8, 5.9 Hz, 1H), 1.41 (s, *J* = 3.3 Hz, 9H), 1.16 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.4, 148.0, 133.9, 133.0, 131.9, 131.0, 124.4, 79.7, 53.0, 49.2, 44.4, 28.4, 18.7. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 466.0647 and 468.0627, found 466.0645, 468.0623 and 366.012, 368.0096 (-Boc).




Tert-butyl (R)-1-((N-(2-bromoethyl)-4-nitrophenyl)sulfonamido)propan-2-yl)carbamate (3b):
 Molecular Formula: C₁₆H₂₄BrN₃O₆S; Rf (40% ethyl acetate/hexanes): 0.25; ¹H NMR (600 MHz, CDCl₃) δ 8.41 – 8.36 (m, 2H), 8.05 – 7.98 (m, 2H), 4.61 (d, *J* = 7.9 Hz, 1H), 3.89-3.84 (m, 1H), 3.59-3.49 (m, 4H), 3.31-3.28 (m, 1H), 3.15 (dd, *J* = 14.1, 6.1 Hz, 1H), 1.44 (s, 9H), 1.21 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.4, 150.2, 145.0, 128.5, 124.5, 79.9, 53.9, 50.5, 45.1, 28.6, 28.4, 18.6. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 466.0647 and 468.0627, found 466.0641, 468.0619 and 366.0116, 368.0092 (-Boc).




Tert-butyl (R)-1-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propan-2-yl)carbamate (3d):
 Molecular Formula: C₁₆H₂₄BrN₃O₆S; Rf (40% ethyl acetate/hexanes): 0.35; ¹H NMR (600 MHz, CDCl₃)

δ 8.04-8.01 (m, 1H), 7.75 – 7.68 (m, 2H), 7.66-7.63 (m, 1H), 4.60 (d, J = 8.5 Hz, 1H), 3.93-3.85 (m, 1H), 3.78 – 3.61 (m, 2H), 3.48-3.45 (m, 3H), 3.26 (dd, J = 14.8, 5.9, 1H), 1.41 (s, 9H), 1.15 (d, J = 6.7 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 148.0, 133.9, 133.0, 131.9, 131.0, 124.4, 79.7, 53.0, 49.2, 44.4, 28.4, 28.1, 18.7. HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 466.0647 and 468.0627 found 466.0640, 468.0618 and 366.0116, 368.0093 (-Boc).




Tert-butyl-(1-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propan-2-yl)carbamate (3e): Molecular Formula: $\text{C}_{16}\text{H}_{24}\text{BrN}_3\text{O}_6\text{S}$; Rf (40% ethyl acetate/hexanes): 0.35; ^1H NMR (600 MHz, CDCl_3) δ 8.05 – 8.01 (m, 1H), 7.75 – 7.68 (m, 2H), 7.67 – 7.63 (m, 1H), 4.59 (d, J = 8.6 Hz, 1H), 3.94-3.85 (m, 1H), 3.77-3.64 (m, 2H), 3.50-3.43 (m, 3H), 3.27 (dd, J = 14.8, 5.8 Hz, 1H), 1.42 (s, 9H), 1.17 (d, J = 6.7 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 148.0, 133.9, 133.0, 131.9, 131.0, 124.4, 79.7, 53.0, 49.8, 44.5, 28.3, 18.7. HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 466.0647 and 468.0627 found 466.0641, 468.0618 and 366.0114, 368.0090 (-Boc).




Tert-butyl (R)-(1-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-4-methylpentan-2-yl)carbamate (3f): Molecular Formula: $\text{C}_{19}\text{H}_{30}\text{BrN}_3\text{O}_6\text{S}$; Rf (40% ethyl acetate/hexanes): 0.4; ^1H NMR (600 MHz, CDCl_3) δ 8.06 – 8.01 (m, 1H), 7.74 – 7.68 (m, 2H), 7.66-7.63 (m, 1H), 4.42 (d, J = 9.4 Hz, 1H), 3.89-3.82 (m, 1H), 3.79-3.68 (m, 2H), 3.50-3.45 (m, 3H), 3.27 (dd, J = 14.9, 5.4 Hz, 1H), 1.74 – 1.64 (m, 1H), 1.40 (s, 9H), 1.32 – 1.19 (m, 2H), 0.91 (t, J = 6.3 Hz, 7H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.7, 148.0, 133.7,


133.3, 131.9, 131.0, 129.2, 124.4, 79.6, 52.3, 49.0, 46.7, 42.1, 28.3, 24.8, 23.3, 21.9. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 508.1117 and 510.1096, found 508.1107, 510.1084 and 408.0581, 410.0558 (-Boc).




Tert-butyl (S)-1-(benzyloxy)-3-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propan-2-yl carbamate (3g); Molecular Formula: $C_{23}H_{30}BrN_3O_7S$; Rf (40% ethyl acetate/hexanes): 0.4; 1H NMR (600 MHz, $CDCl_3$) δ 8.03 (d, $J = 7.9$ Hz, 1H), 7.72-7.68 (m, 1H), 7.67 – 7.61 (m, 2H), 7.39 – 7.35 (m, 2H), 7.34-7.29 (m, 3H), 4.94 (d, $J = 8.8$ Hz, 1H), 4.55 – 4.43 (m, 2H), 3.98-3.93 (m, 1H), 3.78 – 3.68 (m, 2H), 3.61 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.55 – 3.44 (m, 5H), 1.41 (s, 9H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 155.49, 148.06, 137.69, 133.84, 132.80, 131.83, 131.17, 128.50, 127.91, 127.85, 124.37, 79.84, 73.46, 69.33, 49.59, 49.19, 48.59, 28.34. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 572.1066 and 574.1046 found 572.1064, 574.1041 and 472.0539, 474.0516 (-Boc).

General Procedure for the Nosylation (sulfonylation): Into a round bottom flask equipped with magnetic stir bar and septum, the Boc-protected amine (**1 equiv.**) was dissolved in dichloromethane and TEA (**2 equiv.**) was added followed by 2-nitrobenzene sulfonylchloride (2-Nosylchloride, **1.2 equiv.**). The reaction was stirred at room temperature for 2h under nitrogen, after which time TLC and LCMS indicated complete consumption of the starting material. The reaction was diluted with dichloromethane and washed with saturated aq $NaHCO_3$ and brine solution. The organic phase was collected and dried over anhydrous Na_2SO_4 and the solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure product.






Tert-butyl (2-methyl-1-((2-nitrophenyl)sulfonamido)propan-2-yl)carbamate (1h): Molecular Formula: C₁₅H₂₃N₃O₆S; Rf (40% ethyl acetate/hexanes): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.13 – 8.09 (m, 1H), 7.86 – 7.82 (m, 1H), 7.75-7.72 (m, 2H), 5.85 (s, 1H), 4.51 (s, 1H), 3.27 (d, *J* = 6.4 Hz, 2H), 1.38 (s, 9H), 1.28 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 154.6, 148.1, 133.5, 132.8, 131.1, 125.4, 79.8, 52.5, 50.6, 28.3, 25.7. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 374.1386, found 374.1376, 274.0853 (-Boc).




Tert-butyl (1-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-2-methylpropan-2-yl)carbamate (3h): Molecular Formula: C₁₇H₂₆BrN₃O₆S; Rf (40% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 7.95 (d, *J* = 7.6 Hz, 1H), 7.77 – 7.70 (m, 2H), 7.66 (dd, *J* = 7.5, 1.7 Hz, 1H), 4.49 (s, 1H), 3.74 (s, 2H), 3.62 (dd, *J* = 9.2, 7.0 Hz, 2H), 3.50 (dd, *J* = 9.4, 6.9 Hz, 2H), 1.44 (s, 9H), 1.30 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 154.7, 148.4, 134.0, 132.2, 131.8, 130.5, 124.5, 80.0, 54.6, 53.8, 51.0, 28.4, 26.0. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 480.0804 and 482.0783 found 480.0796, 482.0773 and 380.0271, 382.0247 (-Boc).


Note: 3k not purified. After reaction work up, reaction mixture passed through a pad of silica (to eliminate diphenylsulfide by product) and subjected to next reaction.




Tert-butyl (S)-2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propylcarbamate (3m); Molecular Formula: C₁₆H₂₄BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.35; ¹H NMR (600 MHz, CDCl₃) δ 8.08 (dd, *J* = 7.4, 1.9 Hz, 1H), 7.73 (dp, *J* = 7.5, 1.7 Hz, 2H), 7.65 (dd, *J* = 7.5, 1.7 Hz, 1H), 4.92-4.88 (m, 1H), 4.05 – 3.96 (m, 1H), 3.64 – 3.55 (m, 2H), 3.53 – 3.47 (m, 2H), 3.29-3.22 (m, 1H), 3.16-3.10 (m, 1H), 1.38 (s, 9H), 1.16 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.7, 147.9, 134.0, 133.1, 131.9, 131.4, 124.4, 79.7, 54.3, 44.9, 43.8, 29.9, 28.3, 16.8. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 466.0647 and 468.0627 found 466.0639, 468.0616 and 366.0113, 368.0091 (-Boc).




Tert-butyl (S)-2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-4-methylpentylcarbamate (3n); Molecular Formula: C₁₉H₃₀BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.10 – 8.06 (m, 1H), 7.76-7.70 (m, 2H), 7.64 (dd, *J* = 7.4, 1.8 Hz, 1H), 4.94 (t, *J* = 6.0 Hz, 1H), 3.88-3.81 (m, 1H), 3.64-3.54 (m, 3H), 3.46-3.41 (m, 1H), 3.36-3.29 (m, 1H), 3.06 (ddd, *J* = 14.7, 9.6, 5.5 Hz, 1H), 1.63-1.54 (m, 1H), 1.40-1.31 (m, 11H), 0.88 – 0.81 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 156.2, 155.7, 148.0, 134.0, 133.1, 131.9, 131.7, 124.4, 79.6, 56.7, 45.4, 42.4, 40.8, 30.0, 28.3, 28.2, 24.7, 22.6, 22.3. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 508.1117 and 510.1096 found 508.1108, 510.1084 and 408.0579, 410.0557 (-Boc).




Tert-butyl (R)-(2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-4-methylpentyl)carbamate (3o); Molecular Formula: C₁₉H₃₀BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.10 – 8.06 (m, 1H), 7.76-7.70 (m, 2H), 7.64 (dd, *J* = 7.5, 1.7 Hz, 1H), 4.93 (t, *J* = 6.0 Hz, 1H), 3.87-3.82 (m, 1H), 3.64-3.55 (m, 3H), 3.48 – 3.40 (m, 1H), 3.35-3.30 (m, 1H), 3.06 (ddd, *J* = 14.7, 9.6, 5.5 Hz, 1H), 1.62-1.55 (m, *J* = 12.5, 6.2 Hz, 1H), 1.35 (s, 13H), 0.90 – 0.79 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 155.7, 147.9, 134.0, 133.1, 131.9, 131.7, 124.4, 79.6, 56.7, 45.4, 42.4, 40.8, 30.0, 28.3, 28.2, 24.7, 22.6, 22.3. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 508.1117 and 510.1096 found 508.1106, 510.1084 and 408.0581, 410.0558 (-Boc).



Tert-butyl (R)-(2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-3-phenylpropyl)carbamate (3p); Molecular Formula: C₂₂H₂₈BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 7.92 (d, *J* = 7.9 Hz, 1H), 7.69 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.62 (ddd, *J* = 14.6, 7.8, 1.3 Hz, 2H), 7.20-7.13 (m, 3H), 7.07 (d, *J* = 7.3 Hz, 2H), 4.88 (d, *J* = 5.9 Hz, 1H), 4.16 – 4.05 (m, 1H), 3.83 – 3.66 (m, 1H), 3.58-3.49(m, 2H), 3.31 – 3.21 (m, 2H), 2.92 (dd, *J* = 13.8, 5.9 Hz, 1H), 2.76 (dd, *J* = 13.8, 8.8 Hz, 1H), 1.36 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 155.7, 147.8, 136.6, 134.0, 133.0, 132.0, 131.3, 129.1, 128.9, 128.8, 128.8, 127.0, 124.5, 79.6, 59.9, 45.6, 42.0, 38.4, 29.7, 28.3. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 542.0960 and 544.0940 found 542.0959, 544.0938 and 442.0431, 444.0410 (-Boc)




Tert-butyl (R)-3-(benzyloxy)-2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)propylcarbamate (3q); Molecular Formula: C₂₂H₂₈BrN₃O₆S; R_f (50% ethyl acetate/hexanes): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.07 – 8.03 (m, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.57 – 7.48 (m, 2H), 7.37 – 7.28 (m, 3H), 7.23 – 7.16 (m, 2H), 4.87 (t, *J* = 6.0 Hz, 1H), 4.46 – 4.31 (m, 2H), 4.13-4.07 (m, 1H), 3.71 – 3.65 (m, 2H), 3.58 (d, *J* = 5.2 Hz, 2H), 3.54 – 3.45 (m, 2H), 3.39-3.30 (m, 2H), 1.38 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 155.88, 148.12, 137.13, 133.82, 133.10, 131.83, 131.37, 128.64, 128.14, 128.08, 124.28, 79.84, 73.66, 69.48, 58.08, 46.42, 40.43, 29.89, 28.44. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 572.1066 and 574.1046 found 572.1069, 574.1048 and 472.0540, 474.0578 (-Boc).




Tert-butyl (R)-2-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)-2-phenylethylcarbamate (3r); Molecular Formula: C₂₁H₂₆BrN₃O₆S; R_f (50% ethyl acetate/hexanes): 0.35; ¹H NMR (600 MHz, CDCl₃) δ 8.03 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.75 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.71-7.65 (m, 2H), 7.35 (s, 5H), 5.12 (dd, *J* = 8.9, 6.8 Hz, 1H), 4.88-4.83 (m, 1H), 3.80 – 3.68 (m, 2H), 3.67-3.59 (m, 1H), 3.56-3.49 (m, 1H), 3.33-3.28 (m, 1H), 2.73-2.67 (m, 1H), 1.34 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 155.6, 147.9, 135.8, 133.9, 133.5, 132.0, 131.1, 129.2, 129.1, 127.9, 124.3, 79.8, 59.9, 46.4, 40.6, 29.2, 28.3. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 528.0804 and 530.0783 found 528.0807, 530.0784 and 428.0260, 430.0241 (-Boc).

1s and **1t** was prepared according to above discussed general procedure (sulfonylation).





Tert-butyl (S)-(4-((2-nitrophenyl)sulfonamido)butan-2-yl)carbamate (1s); Molecular Formula: $C_{15}H_{23}N_3O_6S$; Rf (50% ethyl acetate/hexanes): 0.3; 1H NMR (600 MHz, $CDCl_3$) δ 8.14 – 8.08 (m, 1H), 7.84-7.81 (m, 1H), 7.73-7.69 (m, 2H), 6.26-6.21 (m, 1H), 4.32 (d, $J = 8.7$ Hz, 1H), 3.79 – 3.66 (m, 1H), 3.3-3.22 (m, 1H), 3.07-2.98 (m, 1H), 1.76 – 1.69 (m, 1H), 1.50 – 1.40 (m, 3H), 1.39 (s, 9H), 1.10 (d, $J = 6.7$ Hz, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 156.0, 148.1, 134.3, 133.3, 132.6, 130.7, 125.1, 79.7, 43.8, 40.8, 38.2, 28.3, 21.5. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 374.1386, found 374.1374 and –Boc 274.0852.




Tert-butyl (R)-4-((2-nitrophenyl)sulfonamido)butan-2-ylcarbamate (1t); Molecular Formula: $C_{15}H_{23}N_3O_6S$; Rf (50% ethyl acetate/hexanes): 0.3; 1H NMR (600 MHz, $CDCl_3$) δ 8.14 – 8.08 (m, 1H), 7.85 – 7.79 (m, 1H), 7.74-7.67 (m, 2H), 6.26-6.21 (bs, 1H), 4.35 – 4.22 (m, 1H), 3.80 – 3.66 (m, 1H), 3.31-3.22 (m, 1H), 3.06-2.99 (m, 1H), 1.77 – 1.68 (m, 1H), 1.39 (s, 9H), 1.10 (d, $J = 6.7$ Hz, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 156.0, 148.1, 134.3, 133.3, 132.5, 131.6, 130.8, 125.1, 124.1, 79.7, 44.3, 43.8, 40.8, 38.2, 28.3, 21.5, 13.7. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 374.1386, found 374.1374 and $-Boc$ 274.0850.

1u was prepared according to above discussed general procedure (sulfonylation).




Tert-butyl 4-((2-nitrophenyl)sulfonamido)butylcarbamate (1u); Molecular Formula: $C_{15}H_{23}N_3O_6S$; Rf (50% ethyl acetate/hexanes): 0.2; 1H NMR (600 MHz, $CDCl_3$) δ 8.14 – 8.09 (m, 1H), 7.87 – 7.83 (m,

1H), 7.76 – 7.72 (m, 2H), 5.41-5.36 (m, 1H), 4.54 (bs, 1H), 3.13-3.06 (m, 4H), 1.62 – 1.54 (m, 2H), 1.54 – 1.47 (m, 2H), 1.42 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 156.0, 148.1, 133.7, 133.6, 132.8, 131.1, 125.4, 79.3, 43.4, 39.8, 28.4, 27.2, 26.9. HRMS (HESI-TOF) m/z calcd for (M + H)⁺ 374.1386, found 374.1377 and -Boc 274.0850.




Tert-butyl (S)-4-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)butan-2-yl)carbamate (3s);
 Molecular Formula: C₁₇H₂₆BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.45; ¹H NMR (600 MHz, CDCl₃) δ 8.04-8.0 (m, 1H), 7.75-7.69 (m, 2H), 7.65 (d, J = 7.6 Hz, 1H), 4.44-4.36 (m, 1H), 3.75 – 3.57 (m, 3H), 3.451-3.41 (m, 3H), 3.39 – 3.28 (m, 1H), 1.81 – 1.65 (m, 2H), 1.44 (s, 9H), 1.14 (d, J = 6.7 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.4, 148.1, 133.9, 132.8, 131.8, 130.8, 124.3, 79.4, 49.6, 46.1, 44.5, 36.4, 28.7, 28.4, 21.3. HRMS (HESI-TOF) m/z calcd for (M + H)⁺ 480.0804 and 482.0783 found 480.0786, 482.07641 and 380.026, 382.0241 (-Boc).




Tert-butyl (R)-4-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)butan-2-yl)carbamate (3t);
 Molecular Formula: C₁₇H₂₆BrN₃O₆S; Rf (50% ethyl acetate/hexanes): 0.45; ¹H NMR (600 MHz, CDCl₃) δ 8.04 – 8.00 (m, 1H), 7.75-7.68 (m, 2H), 7.65 (dd, J = 7.4, 1.9 Hz, 1H), 4.42-4.37 (m, 1H), 3.70-3.67 (m,

2H), 3.65 – 3.58 (m, 1H), 3.49-3.41 (m, 3H), 3.39-3.31 (m, 1H), 1.81 – 1.65 (m, 2H), 1.44 (s, 9H), 1.14 (d, $J = 6.5$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 148.1, 133.8, 132.9, 131.8, 130.9, 124.3, 79.4, 49.6, 46.2, 44.5, 44.2, 36.4, 28.4, 21.3, 13.7. HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 480.0804 and 482.0783 found 480.0792, 482.077 and 380.0268, 382.0246 (-Boc).




Tert-butyl (4-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)butyl)carbamate (3u); Molecular Formula: $\text{C}_{17}\text{H}_{26}\text{BrN}_3\text{O}_6\text{S}$; Rf (50% ethyl acetate/hexanes): 0.5; ^1H NMR (600 MHz, CDCl_3) δ 8.05 – 8.01 (m, 1H), 7.76 – 7.69 (m, 2H), 7.65 (dd, $J = 7.1, 2.1$ Hz, 1H), 4.61 – 4.54 (m, 1H), 3.66 (t, $J = 7.5$ Hz, 2H), 3.46 (t, $J = 7.5$ Hz, 2H), 3.37 (t, $J = 7.6$ Hz, 2H), 3.14-3.06 (m, 2H), 1.60 (p, $J = 7.5$ Hz, 2H), 1.50-1.45 (m, 2H), 1.44 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.0, 148.1, 133.8, 133.0, 131.8, 130.8, 124.3, 79.3, 49.1, 48.3, 39.7, 28.5, 28.4, 27.2, 25.7. HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 480.0804 and 482.0783 found 480.0791, 482.0769 and 380.0267, 382.0244 (-Boc).




Tert-butyl (S)-2-methyl-4-((2-nitrophenyl)sulfonyl)piperazine-1-carboxylate (4a); Molecular Formula: $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}_6\text{S}$; Rf (40% ethyl acetate/hexanes): 0.4; ^1H NMR (600 MHz, CDCl_3) δ 7.95 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.78 – 7.67 (m, 2H), 7.62 (dd, $J = 7.6, 1.6$ Hz, 1H), 4.38 (d, $J = 9.1$ Hz, 1H), 3.95 (d, $J = 13.6$ Hz, 1H), 3.79 (ddt, $J = 12.3, 3.9, 2.0$ Hz, 1H), 3.59 (dt, $J = 12.3, 1.9$ Hz, 1H), 3.18 (td, $J = 13.0, 3.5$ Hz, 1H), 2.94 (dd, $J = 12.4, 3.7$ Hz, 1H), 2.75 (td, $J = 12.3, 3.5$ Hz, 1H), 1.44 (s, 9H), 1.21 (d, $J = 6.8$ Hz,

3H). ^{13}C NMR (151 MHz, CDCl_3) δ 154.2, 148.4, 133.8, 131.5, 131.1, 131.0, 124.1, 80.4, 50.2, 45.8, 28.3, 14.9. $[\alpha]_{\text{D}}^{25}$ -2.7 (c 1.0, MeOH). HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 386.1386, found 286.0849 (-Boc).




Tert-butyl (R)-2-methyl-4-((4-nitrophenyl)sulfonyl)piperazine-1-carboxylate (4b); Molecular Formula: $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}_6\text{S}$; Rf (50% ethyl acetate/hexanes): 0.3; ^1H NMR (600 MHz, CDCl_3) δ 8.42 – 8.37 (m, 2H), 7.96 – 7.91 (m, 2H), 4.37 (s, 1H), 3.95 (d, $J = 13.6$ Hz, 1H), 3.76-3.73 (m, 1H), 3.56-3.54 (m, 1H), 3.18 (dt, $J = 13.0, 3.6$ Hz, 1H), 2.49 (dd, $J = 11.5, 3.8$ Hz, 1H), 2.31 (dt, $J = 11.8, 3.5$ Hz, 1H), 1.42 (s, 9H), 1.29 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 154.0, 150.3, 141.8, 128.8, 124.4, 80.4, 50.3, 45.9, 29.4, 28.3, 15.0. $[\alpha]_{\text{D}}^{25}$ -15 (c 0.5, MeOH). HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 386.1386, found 286.0844 (-Boc).




(S)-3-methyl-1-((2-nitrophenyl)sulfonyl)piperazine (4c); Molecular Formula: $\text{C}_{11}\text{H}_{15}\text{N}_3\text{O}_4\text{S}$; Rf (3% methanol/DCM): 0.3; ^1H NMR (600 MHz, CDCl_3) δ 7.95 (dd, $J = 7.4, 1.9$ Hz, 1H), 7.69 (dp, $J = 7.5, 1.7$ Hz, 2H), 7.60 (dd, $J = 7.3, 1.9$ Hz, 1H), 3.74 – 3.61 (m, 2H), 3.03 (dt, $J = 12.2, 2.6$ Hz, 1H), 2.94 – 2.82 (m, 2H), 2.77 (td, $J = 11.8, 3.1$ Hz, 1H), 2.40 (dd, $J = 11.9, 10.2$ Hz, 1H), 1.06 (d, $J = 6.4$ Hz, 3H). ^{13}C


NMR (151 MHz, CDCl₃) δ 148.5, 133.7, 131.5, 131.2, 130.9, 124.1, 52.5, 50.5, 46.1, 45.5, 19.3. $[\alpha]_D^{25}$ +63.8 (c 1.0, MeOH). HRMS (HESI-TOF) m/z calcd for (M + H)⁺ 286.0862, found 286.0851.




(R)-3-methyl-1-((2-nitrophenyl)sulfonyl)piperazine (4d); Molecular Formula: C₁₁H₁₅N₃O₄S; R_f (3% methanol/DCM): 0.3; **¹H NMR (600 MHz, CDCl₃)** δ 7.96 – 7.93 (m, 1H), 7.69 (dp, J = 7.5, 1.7 Hz, 2H), 7.60 (dd, J = 7.6, 1.7 Hz, 1H), 3.70–3.64 (m, 2H), 3.03 (dt, J = 12.1, 2.6 Hz, 1H), 2.93 – 2.81 (m, 2H), 2.76 (dt, J = 11.8, 3.1 Hz, 1H), 2.38 (dd, J = 11.9, 10.2 Hz, 1H), 1.05 (d, J = 6.4 Hz, 3H). **¹³C NMR (151 MHz, CDCl₃)** δ 148.5, 133.7, 131.5, 130.9, 124.1, 52.5, 50.5, 46.1, 45.5, 19.3. $[\alpha]_D^{25}$ +9.1 (c 2.4, MeOH). HRMS (HESI-TOF) m/z calcd for (M + H)⁺ 286.0862, found 286.0851.




3-methyl-1-((2-nitrophenyl)sulfonyl)piperazine (4e); Molecular Formula: C₁₁H₁₅N₃O₄S; R_f (3% methanol/DCM): 0.3; **¹H NMR (600 MHz, CDCl₃)** δ 7.97 (dd, J = 7.3, 1.9 Hz, 1H), 7.70 (dp, J = 7.5, 1.7 Hz, 2H), 7.61 (dd, J = 7.3, 1.8 Hz, 1H), 3.74 – 3.65 (m, 2H), 3.05 (td, J = 12.1, 2.6 Hz, 1H), 2.95 – 2.85 (m, 2H), 2.80 (dt, J = 11.8, 3.0 Hz, 1H), 2.42 (dd, J = 12.0, 10.2 Hz, 1H), 1.08 (d, J = 6.3 Hz, 3H). **¹³C NMR (151 MHz, CDCl₃)** δ 148.5, 133.6, 131.5, 130.9, 124.1, 52.4, 50.5, 46.0, 45.4, 19.2. HRMS (HESI-TOF) m/z calcd for (M + H)⁺ 286.0862, found 286.0854.




(R)-3-isobutyl-1-((2-nitrophenyl)sulfonyl)piperazine (4f); Molecular Formula: C₁₄H₂₁N₃O₄S; R_f (3% methanol/DCM): 0.35; ¹H NMR (600 MHz, CDCl₃) δ 7.97 – 7.94 (m, 1H), 7.75 – 7.68 (m, 2H), 7.65 – 7.61 (m, 1H), 3.80-3.74 (m, 2H), 3.19 (dt, *J* = 12.2, 2.7 Hz, 1H), 3.09 – 3.01 (m, 1H), 3.0-2.93 (m, 2H), 2.71 – 2.61 (m, 1H), 1.77-1.69 (m, 1H), 1.44-1.39 (m, 1H), 1.38-1.31 (m, 1H), 0.92 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 148.4, 133.9, 131.7, 131.3, 130.9, 124.3, 53.4, 50.3, 45.2, 44.7, 41.5, 24.2, 22.6, 22.5. [α]_D²⁵ -20.0 (c 1.0, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 328.1331, found 328.1322.




(S)-3-((benzyloxy)methyl)-1-((2-nitrophenyl)sulfonyl)piperazine (4g); Molecular Formula: C₁₈H₂₁N₃O₅S; R_f (3% methanol/DCM): 0.4; ¹H NMR (600 MHz, MeOD) δ 8.07 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.90-7.80 (m, 3H), 7.40 – 7.34 (m, 4H), 7.33-7.29 (m, 1H), 4.58 (d, *J* = 2.8 Hz, 2H), 3.94 – 3.81 (m, 2H), 3.63 (dd, *J* = 10.2, 4.6 Hz, 1H), 3.58 (dd, *J* = 10.3, 5.8 Hz, 1H), 3.34 – 3.23 (m, 2H), 3.13 – 3.02 (m, 2H), 2.96 (dd, *J* = 13.1, 10.4 Hz, 1H). ¹³C NMR (151 MHz, MeOD) δ 148.4, 137.4, 134.6, 132.0, 130.8, 130.0, 128.2, 127.8, 127.7, 124.2, 73.2, 67.9, 54.4, 46.1, 43.7, 43.4. [α]_D²⁵ +4.4 (c 2.0, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 392.1280, found 392.1279.




Tert-butyl 2,2-dimethyl-4-((2-nitrophenyl)sulfonyl)piperazine-1-carboxylate (4h): Molecular Formula: $C_{17}H_{25}N_3O_6S$; Rf (40% ethyl acetate/hexanes): 0.3; 1H NMR (600 MHz, $CDCl_3$) δ 8.00 (dd, $J = 7.3, 1.9$ Hz, 1H), 7.74-7.69 (m, 2H), 7.64 (dd, $J = 7.3, 1.9$ Hz, 1H), 3.65 (t, $J = 5.6$ Hz, 2H), 3.41 (t, $J = 5.6$ Hz, 2H), 3.25 (s, 2H), 1.46 (s, 9H), 1.42 (s, 6H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 154.3, 147.1, 132.7, 130.6, 130.6, 130.0, 123.2, 79.5, 54.8, 54.3, 44.3, 39.45, 28.7, 27.4, 23.7. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 400.1542, found 300.1008 (-Boc).




3,3-dimethyl-1-((2-nitrophenyl)sulfonyl)piperazine (4j): Molecular Formula: $C_{12}H_{17}N_3O_4S$; Rf (5% methanol/DCM): 0.4; 1H NMR (600 MHz, $CDCl_3$) δ 7.93 (dd, $J = 7.3, 1.9$ Hz, 1H), 7.72-7.67 (m, 2H), 7.61 (dd, $J = 7.2, 1.9$ Hz, 1H), 3.22-3.21 (m, 2H), 3.06 – 2.95 (m, 4H), 1.17 (s, 6H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 148.4, 133.6, 131.5, 130.9, 124.0, 56.2, 49.7, 46.4, 40.6, 29.7, 25.6. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 300.1018, found 300.1010.




(S)-3-benzyl-1-((4-nitrophenyl)sulfonyl)piperazine (4k); Molecular Formula: C₁₇H₁₉N₃O₄S; R_f (3% methanol/DCM): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.40 (d, *J* = 8.7 Hz, 1H), 7.94 (d, *J* = 8.8 Hz, 1H), 7.32 (t, *J* = 7.5 Hz, 1H), 7.28 – 7.22 (m, 1H), 7.18 – 7.12 (m, 1H), 3.74 – 3.62 (m, 1H), 3.02–2.97 (m, 1H), 2.87 – 2.70 (m, 1H), 2.5–2.44 (m, 1H), 2.18 (t, *J* = 10.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 150.2, 141.9, 136.9, 129.1, 128.8, 127.0, 124.3, 55.8, 51.3, 46.3, 45.0, 39.9. [α]_D²⁵ -25.8 (c 0.5, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 362.1175, found 362.1158.




(S)-2-methyl-1-((2-nitrophenyl)sulfonyl)piperazine (4m); Molecular Formula: C₁₁H₁₅N₃O₄S; R_f (3% methanol/DCM): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.08 – 8.05 (m, 1H), 7.72 – 7.63 (m, 3H), 4.07 (s, 1H), 3.51 (d, *J* = 13.2 Hz, 1H), 3.31 (dt, *J* = 12.7, 2.9 Hz, 1H), 3.04 – 2.93 (m, 2H), 2.84 – 2.69 (m, 2H), 1.31 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 147.8, 133.7, 133.6, 132.1, 132.0, 131.9, 130.9, 128.7, 128.6, 124.5, 49.8, 49.0, 45.2, 40.5, 29.7, 15.5. [α]_D²⁵ +90.6 (c 0.75, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 286.0862, found 286.0851.




(S)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)piperazine (4n); Molecular Formula: C₁₄H₂₁N₃O₄S; R_f (3% methanol/DCM): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.07 (dd, *J* = 7.0, 2.2 Hz, 1H), 7.72 – 7.61 (m, 3H), 3.93-3.89 (m, 1H), 3.63 – 3.56 (m, 1H), 3.31 – 3.24 (m, 1H), 2.93 – 2.82 (m, 3H), 2.67 (dt, *J* = 12.4, 3.5 Hz, 1H), 1.79-1.75 (t, 1H), 1.54-1.49 (m, 1H), 1.47-1.43 (m, 1H), 0.87 (t, *J* = 6.2 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 147.8, 134.3, 133.4, 131.7, 131.0, 124.3, 52.3, 47.9, 45.7, 41.9, 37.7, 24.9, 23.1, 22.1. [α]_D²⁵ +79.7 (c 1.9, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 328.1331, found 328.1323.




(S)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)piperazine (4o); Molecular Formula: C₁₄H₂₁N₃O₄S; R_f (3% methanol/DCM): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.07 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.74 – 7.65 (m, 3H), 4.02-3.96 (m, 1H), 3.69 (dd, *J* = 14.0, 3.5 Hz, 1H), 3.39 (td, *J* = 14.3, 13.4, 3.0 Hz, 1H), 3.07 (d, *J* = 12.5 Hz, 1H), 3.04 – 2.93 (m, 2H), 2.77-2.72 (m, 1H), 1.87 – 1.78 (m, 1H), 1.58 – 1.44 (m, 2H), 0.88 (t, *J* = 6.6 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 147.7, 133.9, 133.7, 131.9, 131.0, 124.5, 51.4, 46.9, 44.8, 40.5, 37.8, 24.9, 22.9, 22.0. [α]_D²⁵ -76.2 (c 2.6, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 328.1331, found 328.1319.




(R)-2-benzyl-1-((2-nitrophenyl)sulfonyl)piperazine (4p); Molecular Formula: C₁₇H₁₉N₃O₄S; R_f (3% methanol/DCM): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 7.95 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.68 – 7.58 (m, 3H), 7.24 – 7.18 (m, 4H), 7.15 (t, *J* = 6.9 Hz, 1H), 4.10-4.05 (m, 1H), 3.70 – 3.63 (m, 1H), 3.44 (dt, *J* = 12.9, 3.1 Hz, 1H), 3.26 (dd, *J* = 13.2, 9.8 Hz, 1H), 3.02 (d, *J* = 12.0 Hz, 1H), 2.95 (dd, *J* = 13.2, 5.4 Hz, 1H), 2.84 (d, *J* = 12.3 Hz, 1H), 2.81-2.75 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 147.6, 138.1, 134.0, 133.3, 131.8, 130.9, 129.4, 128.5, 126.6, 124.4, 55.9, 46.8, 46.1, 42.2, 35.2. [α]_D²⁵ -84.6 (c 2.3, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 362.1175, found 362.1173.




(R)-2-((benzyloxy)methyl)-1-((2-nitrophenyl)sulfonyl)piperazine (4q); Molecular Formula: C₁₈H₂₁N₃O₅S; R_f (3% methanol/DCM): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.06 (td, *J* = 7.7, 1.1 Hz, 1H), 7.61 – 7.54 (m, 3H), 7.33 – 7.27 (m, 3H), 7.24 – 7.21 (m, 2H), 4.49 – 4.36 (dd, 2H), 4.03 (q, *J* = 5.8 Hz, 1H), 3.81 (dd, *J* = 9.6, 6.9 Hz, 1H), 3.71 (dd, *J* = 9.6, 6.1 Hz, 1H), 3.65 – 3.59 (m, 1H), 3.28 (dt, *J* = 13.0, 3.1 Hz, 1H), 3.14 (d, *J* = 12.6 Hz, 1H), 2.98 – 2.86 (m, 2H), 2.72 (dt, *J* = 12.3, 3.5 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 147.70, 137.85, 134.05, 133.27, 131.64, 131.25, 131.07, 129.34, 128.42, 127.73, 127.69, 124.81, 124.24, 73.32, 68.44, 52.61, 46.41, 45.74, 42.81. [α]_D²⁵ +82 (c 0.5, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 392.1280, found 392.1278.




(R)-1-((2-nitrophenyl)sulfonyl)-2-phenylpiperazine (4r); Molecular Formula: C₁₆H₁₇N₃O₄S; R_f (3% methanol/DCM): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 7.88 (d, *J* = 7.9 Hz, 1H), 7.65 (d, *J* = 4.3 Hz, 2H), 7.56 (dq, *J* = 8.5, 4.3 Hz, 1H), 7.36 (d, *J* = 7.2 Hz, 2H), 7.29-7.25 (m, 5H), 7.21 (t, *J* = 7.3 Hz, 1H), 5.05-5.03 (m, 1H), 3.75 – 3.66 (m, 1H), 3.51 (dd, *J* = 13.3, 2.8 Hz, 1H), 3.41 (ddd, *J* = 14.0, 11.2, 3.4 Hz, 1H), 3.22 (dd, *J* = 13.3, 4.1 Hz, 1H), 2.96-2.91 (m, 1H), 2.84 (ddd, *J* = 12.7, 11.2, 3.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 147.7, 137.5, 134.2, 133.3, 131.7, 130.8, 128.7, 127.5, 127.4, 124.2, 56.9, 49.5, 45.6, 43.4. [α]_D²⁵ -89.2 (c 0.9, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 348.1018, found 348.1006.



(S)-5-methyl-1-((2-nitrophenyl)sulfonyl)-1,4-diazepane (4s); Molecular Formula: C₁₂H₁₇N₃O₄S; R_f (5% methanol:DCM): 0.5; ¹H NMR (600 MHz, CDCl₃) δ 8.04 – 7.98 (m, 1H), 7.71-7.66 (m, 2H), 7.64 – 7.60 (m, 1H), 3.64 (td, *J* = 13.8, 3.6 Hz, 1H), 3.56 – 3.41 (m, 2H), 3.31 (ddd, *J* = 13.8, 10.3, 3.5 Hz, 1H), 3.16 (td, *J* = 14.0, 3.7 Hz, 1H), 3.00 – 2.87 (m, 2H), 2.00-1.95 (m, 1H), 1.59-1.52 (m, 1H), 1.15 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 148.1, 133.4, 133.1, 131.6, 130.8, 124.1, 54.2, 51.4, 48.9, 46.6, 38.3, 29.7, 23.2. [α]_D²⁵ +10.9 (c 2.0, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 300.1018, found 300.1005.



(R)-5-methyl-1-((2-nitrophenyl)sulfonyl)-1,4-diazepane (4t); Molecular Formula: C₁₂H₁₇N₃O₄S; R_f (5% methanol:DCM): 0.5; ¹H NMR (600 MHz, CDCl₃) δ 8.02 – 7.99 (m, 1H), 7.72-7.66 (m, 2H), 7.64 – 7.61 (m, 1H), 3.65 (td, *J* = 13.9, 3.6 Hz, 1H), 3.55 – 3.43 (m, 2H), 3.33 (ddd, *J* = 13.8, 10.3, 3.4 Hz, 1H), 3.18 (td, *J* = 14.0, 3.7 Hz, 1H), 3.03 – 2.91 (m, 2H), 2.01-1.96 (m, 1H), 1.62-1.56 (m, 1H), 1.17 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 148.0, 133.4, 133.1, 131.6, 130.8, 124.1, 54.2, 51.1, 48.8, 46.5, 38.1, 29.7, 23.0. [α]_D²⁵ -11.8 (c 2.3, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 300.1018, found 300.1009.




1-((2-nitrophenyl)sulfonyl)-1,4-diazocane (4u); Molecular Formula: C₁₂H₁₇N₃O₄S; R_f (5% methanol:DCM): 0.5; ¹H NMR (600 MHz, CDCl₃) δ 7.94 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.74-7.68 (m, 3H), 7.64 (dd, *J* = 7.4, 1.9 Hz, 1H), 3.59 – 3.49 (m, 4H), 3.22-3.17 (m, 4H), 2.00 – 1.85 (m, 4H). ¹³C NMR (151 MHz, CDCl₃) δ 148.3, 133.7, 132.0, 131.7, 130.7, 124.3, 49.8, 48.8, 48.4, 47.4, 25.8, 24.8. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 300.1018, found 300.1007.


General Experimental Procedure for Annulation: Into a round bottom flask equipped with magnetic stir bar and septum under nitrogen, the bisprotected chiral diamine (**1 equiv.**) was dissolved in dichloromethane and 2-bromoethyl-diphenylsulfonium triflate (**1.25 equiv.**) was added followed by diisopropylethylamine (**3 equiv.**). The reaction was allowed to stir at room temperature under nitrogen for 5h, after which time the TLC and LCMS showed no starting material remaining. The reaction was worked up by diluting with dichloromethane and washed with water and brine. The organic phase was collected and dried over

anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure piperazine product.

Note: Multiple signals of ¹H- and ¹³C-NMR are due to rotamers




(S)-2,2,2-trifluoro-1-(3-methyl-4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one (6a); Molecular Formula: C₁₃H₁₄F₃N₃O₅S; Rf (40% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.11 (td, *J* = 7.5, 1.9 Hz, 1H), 7.78 – 7.69 (m, 3H), 4.54-4.50 (m, 1H), 4.37-4.33 (m, 1H), 4.29 – 4.20 (m, 1H), 4.0-3.95 (m, 1H), 3.78 (dd, *J* = 13.8, 1.8 Hz, 1H), 3.70-3.66 (m, 1H), 3.70 – 3.63 (m, 1H), 3.49 (dd, *J* = 13.8, 3.6 Hz, 1H), 3.40 – 3.27 (m, 2H), 3.07 (dd, *J* = 13.4, 3.7 Hz, 1H), 2.89 (dt, *J* = 13.0, 3.9 Hz, 1H), 1.25 (d, *J* = 6.8 Hz, 2H), 1.19 (d, *J* = 6.9 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 156.56, 156.45, 156.32, 156.21, 147.72, 134.11, 134.09, 133.09, 133.04, 132.15, 131.12, 131.08, 124.66, 124.65, 117.19, 115.31, 50.08, 50.05, 49.58, 49.00, 47.86, 45.85, 45.82, 42.91, 40.50, 39.74, 29.71, 14.90, 14.86, 14.12. [α]_D²⁵ +47.6 (c 0.75, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 382.0685, found 382.0672.




(R)-2,2,2-trifluoro-1-(3-methyl-4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one (6b); Molecular Formula: C₁₃H₁₄F₃N₃O₅S; Rf (40% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.10 (td, *J* = 7.5, 1.8 Hz, 1H), 7.78 – 7.67 (m, 3H), 4.53-4.49 (m, 1H), 4.37-4.33 (m, 1H), 4.29 – 4.20 (m, 1H), 4.00 – 3.93 (m, 1H), 3.81 – 3.70 (m, 1H), 3.7-3.66 (m, 1H), 3.48 (dd, *J* = 13.8, 3.6 Hz, 1H), 3.41 – 3.26 (m, 2H), 3.06 (dd, *J* = 13.4, 3.7 Hz, 1H), 2.89 (dt, *J* = 13.0, 3.9 Hz, 1H), 1.25 (d, *J* = 6.8 Hz, 2H), 1.18 (d, *J* = 6.9 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 156.55, 156.45, 156.31, 156.21, 147.71, 134.12, 134.10,

133.07, 133.02, 132.16, 131.10, 131.06, 124.66, 124.65, 117.22, 117.19, 115.31, 115.28, 50.07, 50.05, 50.03, 49.57, 48.99, 47.85, 45.84, 45.82, 45.80, 42.91, 40.49, 39.73, 29.70, 14.89, 14.85. $[\alpha]_D^{25}$ -56.2 (c 1.0, MeOH). HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 382.0685, found 382.0673.




(R)-1-(3-benzyl-4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)-2,2,2-trifluoroethan-1-one (6c); Molecular Formula: $C_{19}H_{18}F_3N_3O_5S$; Rf (40% ethyl acetate/hexanes): 0.5; 1H NMR (600 MHz, $CDCl_3$) δ 7.96 (dd, $J = 7.9, 1.4$ Hz, 1H), 7.72 – 7.57 (m, 4H), 7.22 – 7.18 (m, 2H), 7.18 – 7.13 (m, 3H), 7.09-7.04 (m, 2H), 4.60 – 4.54 (m, 1H), 4.51-4.46 (m, 1H), 4.38-4.34 (m, 1H), 4.23-4.19 (m, 1H), 4.12 – 3.98 (m, 2H), 3.97 – 3.87 (m, 2H), 3.59 (dd, $J = 13.7, 3.8$ Hz, 1H), 3.54 – 3.42 (m, 2H), 3.35 (dt, $J = 13.1, 3.3$ Hz, 1H), 3.04 – 2.94 (m, 2H), 2.88-2.79 (m, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 147.47, 136.42, 133.92, 133.60, 133.22, 132.21, 131.17, 130.84, 129.41, 128.97, 128.65, 128.48, 127.08, 124.78, 124.71, 56.22, 55.39, 45.98, 44.93, 43.42, 41.37, 40.50, 35.75, 35.47, 29.71, 14.13. $[\alpha]_D^{25}$ -58.0 (c 1.0, MeOH). HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 458.0998, found 458.0994.



(R)-1-(3-benzyl-4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)-2,2,2-trifluoroethan-1-one (6d); Molecular Formula: $C_{19}H_{18}F_3N_3O_5S$; Rf (40% ethyl acetate/hexanes): 0.5; 1H NMR (600 MHz, $CDCl_3$) δ 7.96 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.73 – 7.58 (m, 4H), 7.23 – 7.18 (m, 2H), 7.18 – 7.12 (m, 3H), 7.09-7.04 (m, 2H), 4.60 – 4.55 (m, 1H), 4.51-4.47 (m, 1H), 4.38-4.33 (m, 1H), 4.23-4.19 (m, 1H), 4.09 – 3.97 (m, 2H), 3.98 – 3.87 (m, 2H), 3.59 (dd, $J = 13.7, 3.8$ Hz, 1H), 3.54-3.44 (m, 2H), 3.38-3.32 (m, 1H), 3.06 – 2.94 (m, 2H), 2.88-


2.79 (m, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.65, 147.46, 136.42, 133.92, 133.61, 133.21, 132.22, 132.17, 131.17, 130.83, 129.41, 128.97, 128.65, 128.48, 127.08, 124.78, 124.70, 56.22, 55.39, 48.65, 46.00, 45.97, 44.93, 43.42, 41.37, 40.50, 35.75, 35.46, 29.71, 14.13. $[\alpha]_{\text{D}}^{25} +60.0$ (c 1.3, MeOH). HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 458.0998, found 458.0991



6e

(R)-2,2,2-trifluoro-1-(3-isobutyl-4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one (6e);

Molecular Formula: $\text{C}_{16}\text{H}_{20}\text{F}_3\text{N}_3\text{O}_5\text{S}$; Rf (40% ethyl acetate/hexanes): 0.45; ^1H NMR (600 MHz, CDCl_3) δ 8.12-8.09 (m, 1H), 7.78 – 7.68 (m, 3H), 4.49-4.43 (m, 1H), 4.13 – 4.02 (m, 1H), 3.96-3.92 (m, 1H), 3.85 – 3.78 (m, 2H), 3.46 (dd, $J = 13.8, 3.7$ Hz, 1H), 3.40 – 3.20 (m, 2H), 3.01 (dd, $J = 13.5, 3.7$ Hz, 1H), 2.81 (dt, $J = 13.1, 3.9$ Hz, 1H), 1.58-1.53 (m, 1H), 1.50-1.41 (m, 2H), 1.30 – 1.21 (m, 1H), 0.87 (dd, $J = 14.1, 6.3$ Hz, 3H), 0.81 (dd, $J = 6.4, 2.4$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.67, 156.43, 156.34, 156.10, 147.69, 134.11, 134.09, 133.45, 133.43, 133.39, 132.12, 132.10, 131.17, 131.15, 130.97, 124.71, 124.70, 117.22, 117.18, 115.31, 115.27, 52.30, 51.47, 48.20, 48.18, 45.90, 45.87, 45.85, 45.83, 45.68, 42.78, 40.93, 40.19, 37.92, 37.47, 24.72, 24.49, 22.86, 22.40, 22.38, 22.00. $[\alpha]_{\text{D}}^{25} -71.6$ (c 3.7, MeOH). HRMS (HESI-TOF) m/z calcd for $(\text{M} + \text{H})^+$ 424.1154, found 424.1149.




6f

(S)-2,2,2-trifluoro-1-(4-((2-nitrophenyl)sulfonyl)-3-phenylpiperazin-1-yl)ethan-1-one (6f);

Molecular Formula: $\text{C}_{18}\text{H}_{16}\text{F}_3\text{N}_3\text{O}_5\text{S}$; Rf (40% ethyl acetate/hexanes): 0.4; ^1H NMR (600 MHz, CDCl_3) δ 7.94-7.91 (m, 1H), 7.73-7.70 (m, 2H), 7.67 – 7.56 (m, 2H), 7.27-7.24 (m, 5H), 7.22 – 7.14 (m, 2H), 5.30 (t, $J = 3.8$ Hz, 1H), 5.13 (t, $J = 5.2$ Hz, 1H), 4.87-4.82 (m, 1H), 4.06-4.01 (m, 1H), 4.00 – 3.92 (m, 2H), 3.91 – 3.80 (m, 2H), 3.60 – 3.49 (m, 2H), 3.49 – 3.39 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 156.40, 156.18, 155.94,

147.59, 135.78, 134.93, 133.99, 133.71, 133.67, 133.46, 132.16, 131.73, 130.99, 130.91, 128.95, 128.73, 128.52, 128.28, 127.18, 126.84, 124.57, 124.30, 117.05, 115.15, 58.13, 57.12, 48.65, 45.69, 45.66, 45.07, 43.78, 42.11, 41.92. $[\alpha]_D^{25} +74.7$ (c 2.6, MeOH). HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 444.0841, found 444.0832.


Procedure for the Synthesis of **5g**:




S₆ was prepared according to above discussed general procedure (sulfonylation).

Into a round bottom flask equipped with magnetic stir bar and septum, the compound **S₆** (**1 equiv.**) was dissolved in dichloromethane and TFA (10% TFA in DCM, V/V, 10 mL/mmol) was added and allowed to stir at room temperature under nitrogen. After 3h the starting material was consumed according to LCMS. The volatiles were evaporated under reduced pressure and then redissolved in toluene and evaporated to remove excess TFA. The mixture was dissolved in EtOH and TMSCl (**3 equiv.**) was added at room temperature and the reaction was allowed to stir at room temperature under nitrogen. After 3h, LCMS and TLC showed complete consumption of the starting material. The solvent was removed under reduced pressure to give the crude residue. The crude mixture was diluted with ethyl acetate and washed with saturated aq NaHCO₃ solution. The organic phase was collected and dried over anhydrous Na₂SO₄, and the solvent was removed under reduced pressure to give the crude product which was carried forward to the next step without purification.


Next, into a round bottom flask equipped with magnetic stir bar and septum, the crude amine (**1 equiv.**) was dissolved in dichloromethane and cooled to 0 °C, TEA (**3 equiv.**) and TFAA (**2 equiv.**) was added. The reaction was immediately allowed to come to room temperature and stirred for 2h under nitrogen, after which time LCMS indicated complete consumption of the starting material. The reaction was diluted with dichloromethane and washed with saturated aq. NaHCO₃ and brine solution. The organic phase was collected and dried over anhydrous Na₂SO₄ and the solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure product **5g** (78% yield over three steps).




Tert-butyl (S)-3-((tert-butoxycarbonyl)amino)-4-((2-nitrophenyl)sulfonamido)butanoate (S₆); Molecular Formula: C₁₉H₂₉N₃O₈S; Rf (50% ethyl acetate/hexanes): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 8.12 – 8.09 (m, 1H), 7.88 – 7.84 (m, 1H), 7.76 – 7.70 (m, 2H), 5.88 – 5.75 (m, 1H), 5.16 (d, *J* = 7.9 Hz, 1H), 3.98-3.92 (m, 1H), 3.34-3.28 (m, 1H), 3.23-3.19 (m, 1H), 2.55-2.48 (m, 2H), 1.44 (s, 9H), 1.39 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 170.4, 155.4, 148.1, 133.7, 133.6, 132.9, 131.0, 125.5, 81.7, 80.0, 47.4, 46.5, 37.4, 28.3, 28.0. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 460.1754, found 460.1740.



Ethyl (S)-4-((2-nitrophenyl)sulfonamido)-3-(2,2,2-trifluoroacetamido)butanoate (5g); Molecular Formula: C₁₄H₁₆F₃N₃O₇S; Rf (50% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.14 – 8.09 (m, 1H), 7.92 – 7.86 (m, 1H), 7.81 – 7.75 (m, 2H), 7.59 (d, *J* = 8.3 Hz, 1H), 5.92 (t, *J* = 6.7 Hz, 1H), 4.40-4.35 (m, 1H), 4.21-4.17 (m, 2H), 3.39 (t, *J* = 6.3 Hz, 2H), 2.82 (dd, *J* = 16.9, 5.0 Hz, 1H), 2.72 (dd, *J* = 16.8, 6.3 Hz, 1H), 1.29 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 171.1, 157.3, 157.1, 148.0, 134.0, 133.1, 131.0, 125.6, 116.5, 114.6, 61.5, 46.8, 45.0, 34.6, 14.0. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 428.0739, found 428.0728.




Ethyl (S)-2-(1-((2-nitrophenyl)sulfonyl)-4-(2,2,2-trifluoroacetyl)piperazin-2-yl)acetate (6g); Molecular Formula: $C_{16}H_{18}F_3N_3O_7S$; Rf (50% ethyl acetate/hexanes): 0.4; 1H NMR (600 MHz, $CDCl_3$) δ 7.99-7.96 (m, 1H), 7.78 – 7.70 (m, 2H), 7.69-7.66 (m, 1H), 5.12 – 5.01 (m, 1H), 4.59 – 4.46 (m, 1H), 4.20 – 4.05 (m, 2H), 3.99-3.88 (m, 3H), 3.59-3.53 (m, 1H), 3.23 – 3.02 (m, 2H), 2.98 – 2.89 (m, 1H), 2.82 (dd, $J = 15.9, 8.4$ Hz, 1H), 2.70 – 2.44 (m, 1H), 1.27-1.21 (m, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 169.7, 148.2, 134.3, 131.9, 131.9, 131.2, 131.1, 124.5, 61.3, 61.2, 48.3, 48.0, 46.9, 45.6, 45.3, 41.3, 38.5, 34.0, 33.0, 14.0. $[\alpha]_D^{25} +14.7$ (c 1.0, MeOH). HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 454.0896, found 454.0892.




(S)-2,2,2-trifluoro-N-(4-((2-nitrophenyl)sulfonamido)butan-2-yl)acetamide (5h); Into a round bottom flask equipped with magnetic stir bar and septum, Compound **1s** (1 equiv.) was dissolved in dichloromethane and TFA (10% TFA in DCM, V/V, 10 mL/mmol) was added and allowed to stir at room temperature under nitrogen. After 2h the starting material was consumed according to TLC and LCMS. The volatiles were evaporated under reduced pressure and then redissolved in toluene and evaporated to remove excess TFA. The mixture was dissolved in dichloromethane and cooled to 0 °C, TEA (4 equiv.) and TFAA (2 equiv.) was added. The reaction was immediately allowed to come to room temperature and stirred for 2h under nitrogen, after which time LCMS indicated complete consumption of the starting material. The reaction was diluted with dichloromethane and washed with saturated aq. $NaHCO_3$ and brine solution. The organic phase was collected and dried over anhydrous Na_2SO_4 and the solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/hexanes) provided the pure product **5h** (80% yield over two steps). Molecular Formula: $C_{12}H_{14}F_3N_3O_5S$; Rf (50% ethyl acetate/hexanes): 0.3; 1H NMR (600 MHz, $CDCl_3$) δ 8.13 – 8.06 (m, 1H), 7.89 – 7.81 (m, 1H), 7.77 – 7.72 (m, 2H), 6.68 (d, $J = 8.5$ Hz, 1H), 5.89 – 5.79 (m, 1H), 4.12-4.09 (m, 1H), 3.23-3.17 (m, 1H), 3.07 – 3.02 (m, 1H), 1.89 – 1.80 (m, 1H), 1.78-1.72 (m, 1H), 1.24 (d, $J = 6.7$ Hz, 3H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 157.5, 157.34, 157.1, 156.8, 147.9, 133.8, 133.4, 132.9, 130.7, 125.4, 118.6, 116.7, 114.8, 112.8, 44.2, 40.5, 36.5, 20.2. HRMS (HESI-TOF) m/z calcd for $(M + H)^+$ 370.0685, found 370.0702.

5h was subjected to annulation described above.



S. No	Conditions	Isolated
1	DIPEA, DCM, rt, 5h	S ₇
2	DIPEA, DCM, 80 °C, 48h	S ₇

(S)-N-(4-((N-(2-bromoethyl)-2-nitrophenyl)sulfonamido)butan-2-yl)-2,2,2-trifluoroacetamide (S₇); Molecular Formula: C₁₄H₁₇BrF₃N₃O₅S; Rf (50% ethyl acetate/hexanes): 0.4; ¹H NMR (600 MHz, CDCl₃) δ 8.01 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.78 – 7.69 (m, 2H), 7.66 (dd, *J* = 7.5, 1.6 Hz, 1H), 6.42 (d, *J* = 8.2 Hz, 1H), 4.05-3.98 (m, 1H), 3.76 – 3.61 (m, 2H), 3.50 – 3.45 (m, 2H), 3.45-3.40 (m, 1H), 3.38-3.33 (m, 1H), 1.98 – 1.86 (m, 2H), 1.31 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 156.7, 148.1, 134.1, 132.3, 131.9, 130.8, 124.4, 116.6, 49.8, 45.8, 44.67, 35.2, 28.7, 20.2. HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 476.0103, 478.0082 found 476.0125 and 478.0103.





Synthesis of compound **7** and denosylation of **7** was achieved by following the literature protocol (ref no. 26 in manuscript).


(R)-4-methyl-1-((2-nitrophenyl)sulfonyl)-2-phenylpiperazine (7); Molecular Formula: C₁₇H₁₉N₃O₄S; Rf (60% ethyl acetate/hexanes): 0.3; ¹H NMR (600 MHz, CDCl₃) δ 7.85 – 7.80 (m, 1H), 7.68 – 7.60 (m, 2H), 7.55-7.53 (m, 1H), 7.43 – 7.41 (m, 2H), 7.24 – 7.18 (m, 3H), 5.08 (t, *J* = 3.6 Hz, 1H), 3.75- 3.72 (m, 1H), 3.48-3.44 (m, 1H), 3.18-3.16 (m, 1H), 2.70-2.67 (m, 1H), 2.51 (dd, *J* = 12.0, 4.1 Hz, 1H), 2.24 (s, 3H), 2.15 (td, *J* = 11.3, 3.3 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 147.7, 138.1, 134.3, 133.3, 131.7, 130.6, 128.3, 127.9, 127.5, 124.2, 58.1, 56.9, 54.7, 46.2, 42.9. [α]_D²⁵ -67.7 (c 1.0, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 362.1175 found 362.1162.

(R)-2-(4-methyl-2-phenylpiperazin-1-yl)nicotinonitrile (8); Into a round bottom flask equipped with magnetic stir bar and septum under nitrogen, (*R*)-1-methyl-3-phenylpiperazine hydrochloride (**1 equiv.**) was dissolved in DMF, added diisopropylethylamine (**5 equiv.**) and 2-bromonicotinonitrile (**2 equiv.**) The reaction was allowed to stir at 120 °C under nitrogen for 16h, after which time the LCMS showed no



starting material remaining. The reaction was worked up by diluting with ethylacetate and washed with water and brine. The organic phase was collected and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give the crude residue. Purification by silica gel chromatography (ethyl acetate/ hexanes) provided the pure product (60% from 7). Molecular Formula: C₁₇H₁₈N₄; Rf (80% ethyl acetate/hexanes): 0.2; **¹H NMR (600 MHz, CDCl₃)** ; **¹H NMR (600 MHz, CDCl₃)** δ 8.29 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.77 (dd, *J* = 7.7, 2.0 Hz, 1H), 7.41 – 7.35 (m, 2H), 7.29 – 7.22 (m, 2H), 7.20 – 7.13 (m, 1H), 6.77 (dd, *J* = 7.7, 4.8 Hz, 1H), 5.46 (t, *J* = 4.7 Hz, 1H), 3.88 – 3.77 (m, 1H), 3.62-3.58 (m, 1H), 2.96 (dd, *J* = 11.9, 5.6 Hz, 1H), 2.78-2.75 (m, 1H), 2.73 (dd, *J* = 11.8, 3.8 Hz, 1H), 2.56-2.52 (m, 1H), 2.34 (s, 3H). **¹³C NMR (151 MHz, CDCl₃)** δ 161.7, 151.9, 143.5, 140.6, 128.3, 127.3, 126.8, 117.7, 115.2, 60.0, 58.0, 55.2, 46.2. [α]_D²⁵ +63.8 (c 1.0, MeOH). HRMS (HESI-TOF) *m/z* calcd for (M + H)⁺ 279.1610 found 279.1602.











^1H , ^{13}C -HMBC






DEPTQ-135




















DEPTQ-135





^1H , ^{13}C -HSQC






































^1H , ^{13}C -HSQC























DEPTQ-135





$H^1, ^{13}C$ -HSQC

















































































^1H , ^{13}C -HMBC





DEPTQ-135




^1H , ^{13}C -HSQC















^1H , ^{13}C -HMBC





DEPTQ-135




^1H , ^{13}C -HSQC















DEPTQ-135






H¹, ¹³C-HMBC





$H^1, ^{13}C$ -HSQC















H¹, ¹³C-HMBC





DEPTQ-135





H¹, ¹³C-HSQC
















8.08
8.07
8.06
7.88
7.87
7.87
7.86
7.85
7.84
7.83
7.82
7.81
7.38
7.37
7.37
7.36
7.35
7.35
7.33
7.33
7.32
7.32
7.31
7.31
7.30
7.30


4.60
4.58
4.56
3.92
3.91
3.91
3.89
3.89
3.89
3.87
3.85
3.85
3.65
3.64
3.63
3.62
3.59
3.58
3.57
3.56
3.36
3.35
3.34
3.33
3.33
3.33
3.32
3.32
3.31
3.30
3.29
3.29
3.07
3.07
3.06
3.06
3.05
3.05
2.98
2.97
2.96















DEPTQ-135





4h





$H^1, ^{13}C$ -HMBC





H¹, ¹³C-HSQC











DEPTQ-135





H¹, ¹³C-HSQC


























































7.95
7.95
7.94
7.94
7.93
7.73
7.73
7.72
7.72
7.71
7.71
7.70
7.70
7.69
7.68
7.68
7.67
7.65
7.64
7.63
7.63

3.57
3.57
3.56
3.56
3.55
3.53
3.52
3.51
3.22
3.21
3.20
3.19
3.18
3.17
1.97
1.96
1.96
1.96
1.95
1.95
1.94
1.94
1.93
1.92
1.92
1.91
1.91
1.90
1.90
1.89















8.11
8.11
8.10
8.10
8.09
8.09
7.77
7.77
7.76
7.76
7.75
7.75
7.74
7.74
7.74
7.73
7.73
7.72
7.72
7.71
7.71
7.71
7.70
7.70
7.69
7.69
4.52
4.52
4.52
4.50
4.50
4.50
4.50
4.50
4.36
4.36
4.35
4.35
4.34
4.34
4.33
4.33
4.26
4.26
4.25
4.25
4.24
4.24
4.23
4.23
3.98
3.98
3.96
3.96
3.79
3.79
3.77
3.77
3.74
3.74
3.72
3.72
3.69
3.69
3.69
3.69
3.67
3.67
3.67
3.67
3.50
3.49
3.49
3.47
3.47
3.36
3.36
3.36
3.36
3.34
3.34
3.34
3.33
3.33
3.32
3.32
3.31
3.31
3.30
3.30
3.08
3.07
3.06
3.06
2.89
2.89
1.25
1.25
1.24
1.24
1.19
1.18



















156.67
156.43
156.34
156.10
147.69
134.11
134.09
133.45
133.43
133.39
132.12
132.10
131.17
131.15
130.97
124.71
124.70
117.22
117.18
115.31
115.27


52.30
51.47
48.20
48.18
45.90
45.87
45.85
45.83
45.68
42.78
40.93
40.19
37.92
37.47
24.72
24.49
22.86
22.40
22.38
22.00









































5h


COSY












^1H - ^{13}C HSQC



























Chiral HPLC



=====

Acq. Operator	: SYSTEM	Seq. Line	: 2
Acq. Instrument	: CHIRAL	Location	: 31
Injection Date	: 11/4/2019 6:00:28 PM	Inj	: 1
		Inj Volume	: 5.000 µl


Different Inj Volume from Sample Entry! Actual Inj Volume : 10.000 µl

Method : C:\Chem32\1\Data\Srinivas\HJ-3841 2019-11-04 17-42-18\FAST_Chiral_Scout_IA_nHep_Ethanol.M (Sequence Method)

Last changed : 11/4/2019 5:42:18 PM by SYSTEM

Method Info : Scouting method for normal phase chiral separations ChiralPak IA with n-Heptane and Ethanol

Additional Info : Peak(s) manually integrated




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=210,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.212	MM	0.2906	4.67834e4	2683.20776	50.8881
2	10.332	MM	0.2869	4.51505e4	2623.08179	49.1119

Totals : 9.19339e4 5306.28955



Signal 2: DAD1 B, Sig=220,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.215	MM	0.2389	3.88985e4	2714.01636	49.8514
2	10.335	MM	0.2425	3.91304e4	2689.41455	50.1486


Totals : 7.80289e4 5403.43091

Signal 3: DAD1 C, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.215	MM	0.2257	1.23823e4	914.21948	50.1849
2	10.335	MM	0.2222	1.22910e4	922.11060	49.8151

Totals : 2.46734e4 1836.33008

=====
*** End of Report ***




```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : CHIRAL                     Location  :   31
Injection Date  : 11/6/2019 5:23:51 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 10.000 µl
Method          : C:\Chem32\1\Data\Srinivas\HJ-3841 2019-11-06 17-05-35\FAST_Chiral_Scout_IA_
                 nHep_Ethanol.M (Sequence Method)
Last changed    : 11/6/2019 5:05:35 PM by SYSTEM
Method Info     : Scouting method for normal phase chiral separations ChiralPak IA with n-
                 Heptane and Ethanol
=====

```

Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 A, Sig=210,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.207	MM	0.3490	6.80222e4	2839.32886	97.2292
2	10.701	MM	0.3876	1938.47900	83.35078	2.7708

Totals : 6.99607e4 2922.67964

Signal 2: DAD1 B, Sig=220,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.210	MM	0.3389	6.57790e4	3234.55884	97.6638
2	10.702	MM	0.4054	1573.49976	64.69689	2.3362


Totals : 6.73525e4 3299.25573


Signal 3: DAD1 C, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.208	MM	0.2450	2.61853e4	1780.98474	96.9521
2	10.701	MM	0.3381	823.19885	40.57403	3.0479

Totals : 2.70085e4 1821.55877

=====
*** End of Report ***






4d

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : CHIRAL                      Location  :   41
Injection Date  : 11/6/2019 5:56:14 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Different Inj Volume from Sample Entry! Actual Inj Volume : 10.000 µl
Method         : C:\Chem32\1\Data\Srinivas\HJ-3841 2019-11-06 17-05-35\FAST_Chiral_Scout_IA_
                nHep_Ethanol.M (Sequence Method)
Last changed   : 11/6/2019 5:05:35 PM by SYSTEM
Method Info    : Scouting method for normal phase chiral separations ChiralPak IA with n-
                Heptane and Ethanol
  
```

Additional Info : Peak(s) manually integrated



=====
 Area Percent Report
 =====


```

Sorted By      :      Signal
Multiplier    :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=210,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.454	MM	0.2533	6290.36230	413.85803	8.7974
2	10.375	MM	0.3541	6.52124e4	3069.39160	91.2026

Totals : 7.15028e4 3483.24963



Signal 2: DAD1 B, Sig=220,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.464	MM	0.2715	4615.68848	283.35751	7.1673
2	10.372	MM	0.2943	5.97840e4	3385.49194	92.8327

Totals : 6.43996e4 3668.84946

Signal 3: DAD1 C, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.454	MM	0.1935	997.27118	85.90546	4.3193
2	10.371	MM	0.2462	2.20914e4	1495.26611	95.6807

Totals : 2.30886e4 1581.17157

=====
*** End of Report ***